---
layout: post
title: "Psychopharmacologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Midomafetamine Capsules"
date: 2026-02-05 19:09:33 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-10053
original_published: 2024-05-08 00:00:00 +0000
significance: 8.00
---

# Psychopharmacologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Midomafetamine Capsules

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** May 08, 2024 00:00 UTC
**Document Number:** 2024-10053

## Summary

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Psychopharmacologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/05/08/2024-10053/psychopharmacologic-drugs-advisory-committee-notice-of-meeting-establishment-of-a-public-docket)
- API: https://www.federalregister.gov/api/v1/documents/2024-10053

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
